Stereotactic Radiosurgery with the CyberKnife for Pituitary Adenomas.
10.3340/jkns.2009.45.3.157
- Author:
Chul Bum CHO
1
;
Hae Kwan PARK
;
Won Il JOO
;
Chung Kee CHOUGH
;
Kyung Jin LEE
;
Hyoung Kyun RHA
Author Information
1. Catholic Neuroscience Center, Department of Neurosurgery, St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea. parkoct@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
CyberKnife;
Pituitary adenoma
- MeSH:
Acromegaly;
Adenoma;
Follow-Up Studies;
Humans;
Pituitary Neoplasms;
Prolactinoma;
Radiosurgery;
Treatment Outcome;
Tumor Burden;
Visual Acuity
- From:Journal of Korean Neurosurgical Society
2009;45(3):157-163
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: In recent years, CyberKnife has emerged as an important treatment modality in the management of pituitary adenomas. Treatment results after performing CyberKnife and the complications of this procedure are reviewed. METHODS: Twenty-six patients with pituitary adenomas received stereotactic radiosurgery with the CyberKnife (CKRS). The follow-up periods ranged from 7 months to 47 months (mean+/-SD : 30+/-12.7 months). The patients consisted of 17 with non-functioning adenomas, 3 with prolactinomas and 6 with acromegaly. The change in the tumor volume, visual acuity, hormonal function, and complications by this therapy were analyzed in each case. RESULTS: The tumor control rate was 92.3%. Hormonal function was improved in all of the 9 (100%) functioning adenomas. Hormonal normalization was observed in 4 of the 9 (44%) patients with a mean duration of 16 months. In two patients (7.6%), visual acuity worsened due to cystic enlargement of the tumor after CKRS. No other complications were observed. CONCLUSION: CyberKnife is considered safe and effective in selected patients with pituitary adenomas. However, longer follow-up is required for a more complete assessment of late toxicity and treatment efficacy.
